Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management

Published December 8th, 2009 - 02:08 GMT

HORSHAM, Pa., Dec. 7 /PRNewswire-FirstCall/ -- Teva Respiratory, a division of Teva
Pharmaceutical Industries Ltd. (NASDAQ:TEVA), today announced the publication of
four articles in a special supplement of the December issue of the Journal of
Allergy and Clinical Immunology (JACI), providing a comprehensive scientific review
of the emerging role of the small airways in the understanding and treatment of
asthma. This represents the first time leading researchers from various institutions
in the U.S. and Canada have organized information surrounding the small airways in
asthma to set a benchmark for additional discussion and future research in this

Although increasing evidence supports the importance of small airways in the
diagnosis and treatment of asthma, focused areas of discussion and critical review
of this topic have been lacking. Additionally, while there has been significant
progress in the diagnosis of asthma, including prevention, education and treatment,
asthma remains a major public health concern as millions of people still experience
flare ups and miss school and work days as a result every year.

"It is important for both patients and physicians to have a clear understanding of
the role of the small airways in the pathology of asthma," said study author Richard
J. Martin, MD, Chairman, Department of Medicine, National Jewish Health in Denver,
CO. "Poorly controlled inflammation in the small airways may exacerbate asthma
symptoms, such as coughing and shortness of breath, which may lead to an asthma
attack or need to seek emergency care. Physicians should consider an inhaled
corticosteroid controller medication with a small particle size that delivers
medication to both the large and small airways."

The below chart highlights the four articles included in the supplement that were
developed following the April 2009 symposium at which leading asthma specialists
discussed various aspects surrounding the importance of small airways in asthma

  Article Title                                 Key Highlights
  -------------                                 --------------
  * The Importance and Features                * The small airways play an
    of the Distal Airways in Children            important role in the
    and Adults                                   pathology of asthma
    (E. W. Gelfand and M. Kraft)
                                               * Inflammation of small
                                                 airways may exacerbate
                                                 asthma, contribute to an
                                                 accelerated decline in lung
                                                 function and promote airway

  * Anatomy, Pathology, and Physiology         * Airway inflammation and
    of the Tracheobronchial Tree: Emphasis       remodeling that
    on the Distal Airways                        characterize asthma occur
    (D. M. Hyde, Q. Hamid and C. G. Irvin)       in the small airways

                                               * Small airways are an
                                                 important target for asthma

  * Particle Size of Inhaled Corticosteroids:  * HFA solution metered-dose
    Does it Matter?                              inhalers, such as QVAR(R),
    (C. Leach, G. L. Colice and A. Luskin)       produce small particles
                                                 that are able to reach and
                                                 treat the large and small

                                               * Most inhaled medications do
                                                 not reach the small airways
                                                 where many of the
                                                 pathological changes in
                                                 asthma may occur

                                               * Reformulated QVAR(R) does
                                                 not have greater systemic

  * Imaging of the Distal Airways              * High-resolution CT imaging
    (D. Tashkin and E. E. de Lange)              can assess small airway
                                                 role in asthma

                                               * Traditional imaging methods
                                                 cannot measure small airway


National guidelines recommend inhaled corticosteroids (ICSs) as first-line therapy
to achieve asthma control; however, most of these medications do not reach and treat
the small airways due to their large particle size, therefore, small airway
inflammation remains largely uncontrolled. There are treatments available with
extra-fine particle size, such as QVAR®, which allows asthma control to be delivered
deep in the lung, due to more effective penetration throughout the large and small
airways. Patients should talk to their healthcare provider to learn more about
available treatment options that reach and treat both large and small airways.

* The symposium was funded through an unrestricted grant by Teva Respiratory, LLC.

About Asthma

Asthma is a chronic (long-term), treatable lung disease that causes narrowing of the
large and small airways, making breathing difficult at times. Asthma causes
recurring periods of wheezing (a whistling sound when you breathe), chest tightness,
shortness of breath and coughing that often occurs at night or early in the morning.
Without appropriate treatment, asthma symptoms may become more severe and result in
an asthma attack, which can lead to hospitalization and even death.

Asthma affects people of all ages, but it most often starts in childhood. In the
U.S., more than 22 million people are known to have asthma, including more than 6
million children. Each year in the U.S., asthma causes approximately 500,000
hospitalizations, 134 million days of restricted activity and 4,000 deaths.

About QVAR®

QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol is indicated in the
maintenance treatment of asthma as prophylactic therapy in patients 5 years of age
or older. QVAR® is also indicated for asthma patients who require systemic
corticosteroid administration, where adding QVAR® may reduce or eliminate the need
for systemic corticosteroids.

Important Safety Information

QVAR® is not a bronchodilator and is not indicated for relief of acute bronchospasm.
 Common side effects associated with the use of QVAR® and placebo in clinical trials
includes, but is not limited to, headache (12% and 9%, respectively) and pharyngitis
(8% and 4%, respectively). Caution: Adrenal insufficiency may occur when
transferring patients from systemic steroids (see WARNINGS, Prescribing
Information).  A reduction in growth velocity in growing children and teenagers may
occur as a result of inadequate control of chronic diseases such as asthma or from
use of corticosteroids for treatment.

For full Prescribing Information please click here:

About Teva Respiratory

Teva Respiratory is the U.S.-based respiratory division of Teva Pharmaceutical
Industries Ltd. Teva Pharmaceutical Industries Ltd., headquartered in Israel, is
among the top 20 pharmaceutical companies in the world and is the leading generic
pharmaceutical company. The company develops, manufactures and markets generic and
innovative human pharmaceuticals and active pharmaceutical ingredients. Over 80
percent of Teva's sales are in North America and Europe.


Source: Teva Respiratory, a division of Teva Pharmaceutical Industries, Ltd.

CONTACT:  Denise Bradley, +1-215-591-8974,

© 2000 - 2019 Al Bawaba (

You may also like